您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8473 处方药 8099 非处方药 268 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 日本药房
产地国家: 日本
所属类别: 抗癌药物->肝细胞癌
处方药:处方药
包装规格: (70毫克/瓶+4毫升/瓶)/套
计价单位:
  点击放大  
生产厂家中文参考译名:
大日本住友製薬
生产厂家英文名:
Dainihon Sumitomo
该药品相关信息网址1:
http://www.cqvip.com/qk/94627X/200910/32288079.html
该药品相关信息网址2:
http://www.jpubb.com/en/press/13849/
该药品相关信息网址3:
http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=197658
原产地英文商品名:
Miripla(ミリプラ)(70mg/vial+4ml/vial)/kit
原产地英文药品名:
miriplatin
中文参考商品译名:
Miripla(ミリプラ) (70毫克/瓶+4毫升/瓶)/套
中文参考药品译名:
米铂
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
HCC
临床试验期:
完成
中文适应病症参考翻译1:
肝细胞癌
药品信息:

友情提示:此款药品必须成套购买,一套里面包含70毫克药品和4ML瓶装溶液!

--------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201032222060936.pdf)的“原文Priscribing Information”为准

--------------------------------------------------------------

部分Miripla 处方资料(仅供参考)

日本药品和食品卫生理事会的一个评审委员会推荐批准大日本住友公司的Miriplamiriplatin)用于肝细胞癌(HCC)的治疗。同时获得肯定推荐的有ToaYakushin公司的万古霉素(vancomycin)眼科软膏配方,用于范围广泛的眼科感染。这2个产品最终要在今后几个月内经过厚生劳动省(MHLw)的批准,而miriplatin的批准将是世界范围内的第一次。

--------------------------------------------------------------------------------

October 16, 2009 -- Dainippon Sumitomo Pharma Co., Ltd. (Head Office: Osaka, ; President: Masayo Tada) announces that the Company has obtained a manufacturing and marketing approval for “MIRIPLA® for intra-arterial injection 70 mg” (generic name: miriplatin hydrate), a therapeutic agent for hepatocellular carcinoma in as of October 16, 2009 from Ministry of Health, Labor and Welfare.

MIRIPLA®” is first suspended in an oily lymphographic agent and then administered through hepatic artery into hepatocellular carcinoma. As such an oily lymphographic agent, the Company has “MIRIPLA® suspension vehicle 4 mL” (generic name: iodine addition products of the ethylesters of the fatty acids obtained from  poppyseed oil), which is approved for suspending  MIRIPLA®. The manufacturing and marketing approval for this suspension vehicle was obtained on August 20, 2009 from the competent Ministry.

Lipiodolization” or “Chemo-lipiodlization” is one of the standard methods for treating hepatocellular carcinoma , where an anticancer drug is suspended in an oily lymphographic agent (iodine addition products of the ethylesters of the fatty acids obtained from  poppyseed oil,  Lipiodol) and then administered into hepatic artery. The Company has carried out a research program to discover an anticancer drug suitable for this treatment and succeeded in development of a lipophilic platinum complex, miriplatin which has high affinity to  Lipiodol.

MIRIPLA®has a high suspensibility in “MIRIPLA® suspension vehicle 4 mL “. Some of the characteristics of MIRIPLA®are: it accumulates and stays in a tumor after the administration into hepatic artery, platinum component is released gradually over a long duration and yet exposure to entire body is minor. In clinical tests on hepatocellular carcinoma, satisfactory anti-tumor effects were confirmed not only on patients of initial treatment but also on patients who relapsed after treatment such as hepatic resection. Some side effects were observed, but they were regarded as those generally observed under chemo-lipiodolization therapy, and they were thought to be tolerable at medical institutions familiarized with this treatment. There was no adverse event on vessel disorder in hepatic artery related to this drug.

The Company has an intention to launch both “MIRIPLA® for intra-arterial injection 70 mg” and “MIRIPLA® suspension vehicle 4 mL” after they are listed on the national health insurance drug price standard. As a result of launching of MIRIPLA®, the Company expects to increase the line-up of products for the liver diseases, which includes Sumiferon®, a natural interferon-alpha product, and to further contribute to the total care of liver diseases. 

--------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201032222060936.pdf)的“原文Priscribing Information”为准
--------------------------------------------------------------

更新日期: 2012-3-27
附件:




201032222060936.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com